Table 1.
Clinicopathological and IHC characteristics of all TNBC patients.
| Age (yrs) | 53.4 ± 9.7 | Tumor size (cm) | 2.44 ± 0.84 |
|---|---|---|---|
| Surgical type | Pathological type | ||
| MRM | 82 (71.9%) | IDC | 104 (91.2%) |
| M+SLNB | 32 (28.1%) | DCIS | 2 (1.8%) |
| Chemotherapy | ILC | 2 (1.8%) | |
| Taxane-based | 87 (76.3%) | Others | 6 (5.3%) |
| Non-taxane-based | 18 (15.8%) | Histological grade | |
| Unknown | 9 (7.9%) | I and II | 38 (33.3%) |
| Radiotherapy | III | 76 (66.7%) | |
| Yes | 31 (27.2%) | LNM | |
| No | 73 (64.0%) | Yes | 35 (30.7%) |
| Unknown | 10 (8.8%) | No | 79 (69.3%) |
| Follow up (month) | 63 (57–70) | Ki-67 (%) | 60 (30–70) |
Categorical data are presented as number (%). Numerical data are presented as mean ± SD or median (IQR).
DCIS, Ductal carcinoma in situ; IDC, Infiltrative ductal carcinoma; ILC, Infiltrative lobular carcinoma; IQR, Interquartile range; LNM, Lymph node metastasis; M, Mastectomy; MRM, Modified radical mastectomy; SLNB, Sentinel lymph node biopsy.